Through the MedTech Actuator Accelerator, Neurogen Global has made significant strides in developing a minimally invasive approach to treating neurological conditions.

The program provided access to clinical mentors, regulatory guidance, and investor networks that have been instrumental in advancing the technology toward pre-clinical trials. Ruwini joined the accelerator with a bold hypothesis and leaves with a validated pathway to commercialisation.